Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 371-378

  Costa Pereira, A P ^a   Cotter, T G ^a  

^a NONE

Author keywords

Apoptosis; Caspases; Fas; Prostate cancer; Reactive oxygen intermediates

Indexed keywords

ANDROGEN; CAMPTOTHECIN; CASPASE; FAS ANTIGEN; FAS LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CASPASES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; FAS LIGAND PROTEIN; HUMANS; IMMUNOGLOBULIN M; MALE; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED;

EID: 0032903236     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690365     Document Type: Article

References (38)

1. Buttke TM and Sandstrom PA (1994) Oxidative stress as a mediator of apoptosis. Immunol Today 15: 7-10
2. Carter HB and Coffey DS (1990) The prostate: an increasing medical problem. Prostate 16: 187-197
3. Chung LWK (1995) The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 23: 33-42
4. Clément M-V and Stamenkovic I (1996) Superoxide anion is a natural inhibitor of Fas-mediated cell death. EMBO J 15: 216-225
5. Costa-Pereira AP and Cotter TG (1999) Metabolic alterations associated with apoptosis. In Apoptosis - a Practical Approach, Studinzski G (ed). Oxford University Press: Oxford
6. Denmeade SR, Lin XS and Isaacs JT (1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265
7. Dobbelsteen DJ van den, Nobel CSI, Schlegel J, Cotgreave IA. Orrenius S and Slater AFG (1996) Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 271: 15420-15427
8. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH (1997) Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935-943
9. Enari M, Talanian RV, Wong WW and Nagata S (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (Lond) 380: 723-726
10. Figueroa JA, Lee AV, Jackson JG and Yee D (1995) Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 80: 3476-3482
11. Friesen C, Herr I, Krammer PH and Debatin K-M (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukaemia cells. Nature Med 2: 574-577
12. Gorman AM, Samali A, McGowan AJ and Cotter TG (1997a)The use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry 29: 97-105
13. Gorman AM, McGowan AJ and Cotter TG (1997b) Role of peroxide and Superoxide anion during tumour cell apoptosis. FEBS 404: 27-33
14. Green DR (1997) A Myc-induced apoptosis pathway surfaces. Science 278: 1246-1247
15. Herr I, Wilhelm D, Böhler T, Angel P and Debatin K-M (1997) Activation of CD95 (APO-1/Fas) signalling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16: 6200-6208
16. Hsiang YH, Likan MG and Liu LF (1989) Arrest of replication forks by drug stabilised topoisomerase-I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082
17. Huggins C and Hodges CV (1941) Studies on prostate cancer. I. The effect of castration, of oestrogen, and androgen injection on serum phosphatases in melastatic carcinoma of the prostate. Cancer Res 1: 293-297
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature (Lond) 388: 190-195
19. Isaacs WB, Carter BS and Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-1720
20. Kasahara Y, Iwai K, Yachie A, Ohta K, Konno A, Seki H, Miyawaki T and Taniguchi N (1997) Involvement of reactive oxygen intermediates in spontaneous and CD95(Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89: 1748-1753
21. Kroemer G (1997) Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis in evolution. Cell Death Differ 4: 443-456
22. Lennon SV, Martin SJ and Cotter TG (1990) Dose-dependent induction of apoptosis in human tumour cell lines by widely diverse stimuli. Cell Prolif 24: 203-204
23. Longthorne VL and Williams GT (1997) Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J 16: 3805-3812
24. McGahon AJ, Costa-Pereira AP, Daly L and Cotter TG (1998) Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br J Haematol 101: 539-547
25. McGowan AJ, Fernandes RS, Verhaegen S and Cotter TG (1994) Zinc inhibits UV radiation-induced apoptosis but fails to prevent subsequent cell death. Int J Radiat Biol 66: 343-349
26. McGowan AJ, Ruiz-Ruiz MC, Gorman AM, Lopez-Rivas A and Cotter TG (1996) Reactive oxygen intermediate(s) (ROI): common mediator(s) of poly (ADP-ribose polymerase (PARP) cleavage and apoptosis. FEBS 392: 299-303
27. McGowan AJ, Bowie AG, O'Neill LAJ and Cotter TG (1998) The production of a reactive oxygen intermediate (ROI) during the induction of apoptosis induced by cytotoxic agents. Exp Cell Res. 238: 248-256
28. Müller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 404-413
29. Nagata S (1997) Apoptosis by death factor. Cell 88: 355-365
30. Oehm A, Berhmann I, Falk W, Pawlita M, Maier G, Klas G, Li-Weber CM, Richards S, Dhein J, Trauth BC, Ponsting H and Krammer PH (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 267: 10709-10715
31. Owen-Shaub LB, Radinsky R, Kruzel E, Berry K and Yonehara S (1994) Anti-Fas on non-hematopoietic tumours: levels of Fas/APO-1 and bel-2 are not predictive of biological responsiveness. Cancer Res 54: 1580-1586
32. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umanski SR, Glover RA and Cohen MB (1997) Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57: 1758-1768
33. Schulze-Osthoff K, Krammer P and Droge W (1994) Divergent signalling via APO-1/Fas and the TNF receptor, two homologues molecules involved in physiological cell death. EMBO J 13: 4587-4596
34. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R and Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signalling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331-3334
35. Yagoda A and Petrylak D (1992) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 70: 329-334
36. Yonehara S, Ishi A and Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a surface antigen codownregulated with the receptor of tumour necrosis factor. J Exp Med 181: 1747-1756
37. Widmann C, Gibson S and Johnson GL (1998) Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 273: 7141-7147
38. Wyllie AH, Kerr JFR and Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306